As NKG2A is (co-)expressed on many NK cells, including KIR positive subsets, we follow up on our previous findings by investigating whether (co-)expression of NKG2A is beneficial, due to enhanced NK cell licensing, or detrimental due to inhibitory interactions with HLA-E for the NK cell anti-MM response. The gene discussed is KLRC1; the disease is Miyoshi myopathy.